Related references
Note: Only part of the references are listed.State-of-the-Art Review on Myelofibrosis Therapies
Fuping Wang et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Helen T. Chifotides et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
Margherita Maffioli et al.
BLOOD ADVANCES (2022)
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
Claire N. Harrison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Vikas Gupta et al.
LEUKEMIA & LYMPHOMA (2021)
Next Generation Therapeutics for the Treatment of Myelofibrosis
Douglas Tremblay et al.
CELLS (2021)
MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials
Claire Harrison et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri et al.
CANCER (2020)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Francesca Palandri et al.
ONCOTARGET (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Kate J. Newberry et al.
BLOOD (2017)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
Share Paper
